Find your next paid study

Boehringer IngelheimNCT07472517

~$50 – $2,250

Actual pay is set by the research site.

Advanced Solid TumorNon Small Cell Lung CancerUntreated Advanced NSCLC+1 more

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination t…

Actual pay is set by the research site.

SynthekineNCT05098132

Solid TumorNSCLCColorectal Cancer+2 more

A First-in-Human Phase 1/2 Dose Escalation and Treatment Optimization Study Evaluating Safety, Tolerability, and Preliminary Efficacy of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET

This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of \[225Ac\]Ac-FL-261, a targeted…

Full-Life Technologies UK LimitedNCT07873450

~$150 – $4,200

Actual pay is set by the research site.

Solid Tumor, AdultMetastatic Solid TumorRefractory Cancer+4 more

An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monocl…

Actual pay is set by the research site.

Sairopa B.V.NCT05856981

LiposarcomaProstate CancerAdvanced Breast Cancer+2 more

A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 adm…

Non-small Cell Lung CancerNSCLC

Actual pay is set by the research site.

PfizerNCT04557449

Phase 3

Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without mainte…

Merck Sharp & Dohme LLCNCT06422143

~$50 – $2,100

Actual pay is set by the research site.

Non-Small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor …

Pierre Fabre MedicamentNCT06043817

Actual pay is set by the research site.

NSCLCNon-Small Cell Lung CancerLung Cancer+7 more

A Phase Ib/II Study of STAR0602 With Nivolumab in Non-Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

Background: Immunotherapy is a type of treatment that works by making the body s own immune system stronger. These treatments are used for cancers such as non…

National Cancer Institute (NCI)NCT07902921

~$150 – $2,700

Actual pay is set by the research site.

Locally Advanced or Metastatic Solid TumorsEsophageal Squamous Cell CancerHead and Neck Squamous Cell Cancer+3 more

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combinati…

Actual pay is set by the research site.

ExelixisNCT06545331

Pancreatic Ductal AdenocarcinomaEsophageal CancerCarcinoma, Non-Small-Cell Lung (NSCLC)+2 more

A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08098488 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS.

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (ca…

Actual pay is set by the research site.

PfizerNCT07903415

Locally Advanced /Metastatic Solid TumorsLocally Advanced / Metastatic Solid TumorsMetastatic Solid Cancers+5 more

SI-B036-ST-101: A Multicenter, Open-Label, Phase 1/1b, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SI-B036 in Adult Patients With Advanced/Metastatic Solid Tumors That Are Refractory to Standard Therapies

The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of…

SystImmune Inc.NCT07857616

~$150 – $4,200

Actual pay is set by the research site.

Phase 3

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (O…

Non-small Cell Lung Cancer (NSCLC)